DAR-0100A

DB16139InvestigationalSmall molecule

DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).

Mechanism: Pharmacologically active on Dopamine receptor D1
Curator reviewed
Formula / weight: C₁₇H₁₇NO₂ · 267.328 g/mol (avg)
Also known as: Dihydrexidine, (+)-
Code names: DAR-0100A

Resolves to

Compound

UNIIQ3PJ4B4D0XCAS174691-84-0ChEMBLCHEMBL25856ChEBI124993

Structure

InChIKeyBGOQGUHWXBGXJW-RHSMWYFYSA-NSMILES[H][C@@]12CCC3=C(C=C(O)C(O)=C3)[C@@]1([H])C1=C(CN2)C=CC=C1

Targets

P21728DRD1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with DAR-0100A, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account